Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has announced the selection of four abstracts for poster presentation at the 2020 virtual European Society for Medical Oncology Congress.
Karyopharm to present four posters at the 2020 ESMO Congress
The company will present three abstracts from investigator-sponsored trials featuring XPOVIO (Selinexor) data. XPOVIO is Karyopharm’s first-in-class oral Selective Inhibitor of Nuclear Export compound. Karyopharm will present data of XPOVIO in combination with carboplatin and paclitaxel in treating metastatic/ advanced solid tumors, its combination with pembrolizumab in treating melanoma, as well as data of the combination of selinexor with topotecan in treating metastatic/advanced solid tumors. The fourth abstract will focus on machine learning use in investigating characteristics related to the efficacy and tolerability of XPOVIO.
Sharon Shacham, the Chief Scientific Officer and President of the company said they are delighted to share the additional clinical data for several XPOVIO studies at ESMO this year. This highlights XPOVIO application’s potential in treating solid tumors, which is an important area for pipeline expansion in the future. Sharon added that they are encouraged by the results from the Phase 1b trial of XPOVIO combination with pembrolizumab, which showed enhanced clinical activity as a frontline therapy relative to the historic frontline single-agent pembrolizumab in metastatic nob-uveal melanoma patients.
XPOVIO combination with paclitaxel and carboplatin showed significant clinical activity
Sharon also added that the combination of XPOVIO with paclitaxel and carboplatin showed considerable clinical activity with lasting objective responses, which offers more research in tumor types where carboplatin and paclitaxel chemotherapy applies as a standard cares. The promising results from the combination studies warrant more studies into the possible use of XPOVIO in treating solid tumors.
XPOVIO works by inhibiting nuclear export protein exportin 1 through selective binding to it. The oral SINE compound blocks the nuclear export of tumor suppressors, anti-inflammatory, and growth regulatory proteins resulting in protein accumulation in the nucleus and thus enhancing anti-cancer activity in the cell. Forced nuclear retention of the proteins can counteract several oncogenic pathways that will allow cancer cells to multiply in unrestrained versions if unchecked.
